Role of angiotensin-converting enzyme inhibition in glucose metabolism and renal injury in diabetes

Metabolism: Clinical and Experimental

Volumn 47, Issue SUPPL.1, 1998, Pages 7-11

  Velasquez, Manuel T ^a   Bhathena, Sam J ^b   Striffler, John S ^b   Thibault, Nancy ^b   Scalbert, Elizabeth ^b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; POTASSIUM; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; CONFERENCE PAPER; DIABETIC NEPHROPATHY; ENZYME INHIBITION; GLOMERULOPATHY; GLUCOSE METABOLISM; HEMODYNAMICS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; KIDNEY INJURY; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; GLUCOSE; HUMANS; KIDNEY DISEASES;

EID: 0031677837     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90363-8     Document Type: Article

References (64)

1. Fuller JH: Epidemiology of hypertension with diabetes mellitus. Hypertension 7:II-113-II-117, 1985 (suppl 2)
2. Kannel WB, Wilson PWF, Zhang TJ: The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 121:1268-1273, 1991
3. Eschwege P, Richard JL, Thibault N, et al: Coronary heart disease mortality in relation with diabetes, blood glucose, and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res 15:41-46, 1985 (suppl)
4. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, et al: Coronary heart disease in young type I (insulin-dependent) diabetic patients with and without diabetic nephropathy: Incidence and risk factors. Diabetologia 30:144-148, 1987
5. Panzram G: Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30:123-131, 1987
6. Mogensen CE: High blood pressure as a factor in the progression of diabetic nephropathy. Acta Med Scand Suppl 602:29-32, 1976
7. US Renal Data System: USRDS 1996 Annual Data Report. Bethesda, MD, National Institutes of Health. National Institute of Diabetes and Digestive and Kidney Diseases, April 1996
8. Jauch KW, Hartl W, Guenther B, et al: Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 17:448-454, 1987
9. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321:868-873, 1989
10. Ferner C, Ferrari P, Weidmann P, et al: Antihypertensive therapy with CA+2 antagonist verapamil and/or ACE inhibitor enalapril in NIDDM patients. Diabetes Care 14:911-914, 1991
11. Moore MP, Elliott TW, Nichols MG: Hormonal and metabolic effects of enalapril treatment in hypertensive subjects with NIDDM. Diabetes Care 11:397-401, 1988
12. Paolliso G, Gambardella A, Verza M, et al: ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 6:175-179, 1992
13. Santoro D, Natali A, Palombo C, et al: Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension 20:181-191, 1992
14. Donnelly R: Angiotensin-converting enzyme inhibitors and insulin sensitivity: metabolic effects in hypertension, diabetes, and heart failure. J Cardiovasc Pharmacol 20:S38-S44, 1992 (suppl 11)
15. Corcoran JS, Perkins JE, Hoffbrand BI, et al: Treating hypertension in non-insulin-dependent diabetes: A comparison of atenolol, nifedipine, and captopril combined with bendrofluazide. Diabetic Med 4:164-168, 1987
16. Bilo HJG, Westerman RF, Nicolas-Mereus AM, et al: Effect of enalapril with and without hydrochlorothiazide in hypertensive patients with non-insulin-dependent diabetes mellitus. Diabetes Res 9:21-25, 1988
17. Prince MJ, Stuart CA, Padia M, et al: Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patient: Enalapril for hypertensive diabetics. Arch Intern Med 148:2363-2368, 1988
18. Seefeldt T, Orskov L, Mengel A, et al: Lack of effect of angiotensin-converting enzyme (ACE)-inhibitors on glucose metabolism in type 1 diabetes. Diabetic Med 7:700-704, 1990
19. Reneland R, Andersson PE, Haenni A, et al: Metabolic effects of long-term angiotensin converting enzyme inhibition with fosinopril in patients with essential hypertension: Relationship to angiotensin-converting enzyme inhibition. Eur J Clin Pharmacol 46:431-436, 1994
20. Haenni A, Andersson PE, Lind L, et al: Electrolyte changes and metabolic effects of lysinopril/bendrofluazide treatment. Am J Hypertens 7:615-622, 1994
21. Andersson PE, Lithell: Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men: Relationship to changes in skeletal muscle blood flow. Am J Hypertens 9:323-333, 1996
22. Shionoiri H, Miyakawa T, Takasaki I, et al: Glucose tolerance during chronic captopril therapy in patients with essential hypertension. J Cardiovasc Pharmacol 9:160-164, 1987
23. Shionoiri H, Sugimoto K, Minamisawa K, et al: Glucose and lipid metabolism during long-term treatment with cilazapril in hypertensive patients with or without impaired glucose metabolism. J Cardiovasc Pharmacol 15:933-938, 1990
24. Ludvik B, Kueenburg E, Brunnbauer M, et al: The effects of ramipril on glucose tolerance, insulin secretion, and insulin sensitivity in patients with essential hypertension. J Cardiovasc Pharmacol 18:157-159, 1991
25. Michaelis OE IV, Ellwood KC, Judge JM, et al: Effect of dietary sucrose on the SHR/N-corpulent rat: A new model for insulin-independent diabetes. Am J Clin Nutr 39:612-18, 1984
26. Michaelis OE IV, Patrick DH, Hansen CT, et al: Spontaneous hypertensive/NIH-corpulent rat. Animal model for insulin-independent diabetes mellitus (type II). Am J Pathol 123:398-400, 1986
27. Striffler JS, Bhathena SJ, Michaelis OE IV, et al: Long-term effects of perindopril on metabolic parameters and the heart in the spontaneously hypertensive/NIH-corpulent rat with non-insulin-dependent diabetes mellitus and hypertension. Metabolism 47:1199-1204, 1998
28. Bak JF, Gerdes LU, Sorensen NS, et al: Effect of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients. Am J Med 92:69S-72S, 1992
29. Baba T, Neugebauer S: The link between insulin resistance and hypertension: Effects of antihypertensive and antihyperlipidemic drugs on insulin sensitivity. Drugs 47:383-404, 1994
30. Gall M-A, Rossing P, Skott P, et al: Placebo-controlled comparison of captopril, metoprolol, and hydrochlorothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension. Am J Hypertens 5:257-265, 1992
31. Meyer HU, Curchod B, Maeder E, et al: Modifications of glucose storage in nonobese diabetics, measured by continuous indirect calorimetry. Diabetes 29:752-756, 1980
32. Young AA, Bogardus C, Wolfe-Lopez D, et al: Muscle glycogen synthesis and disposition of infused glucose in humans with reduced rates of insulin-mediated carbohydrate storage. Diabetes 37:303-308, 1988
33. Leighton B, Cooper GJS: Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 335:632-635, 1988
34. Kreutter DK, Orena SJ, Torchia AJ, et al: Amylin and CGRP induce insulin resistance via a receptor distinct from cAMP-coupled CGRP receptor. Am J Physiol 264:E606-E613, 1993
35. Rosenthal T, Erlich Y, Rosenmann E, et al: Effects of enalapril, losartan, and verapamil on blood pressure and glucose metabolism in the Cohen-Rosenthal diabetic hypertensive rat. Hypertension 29:1260-1264, 1997
36. Henriksen EJ, Jacob S: Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism 44:267-272, 1995
37. Steffes ER, Osterby R, Chavers B, et al: Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 38:1077-1081, 1989
38. Bader R, Bader H, Grund KE, et al: Structure and function of the kidney in diabetic glomerulosclerosis: Correlations between morphological and functional parameters. Pathol Res Pract 167:204-216, 1980
39. Thomsen OF, Andersen AR, Christiansen JS, Deckert T: Renal changes in long-term type 1 (insulin-dependent) diabetic patients with and without clinical nephropathy. Diabetologia 26:361-365, 1984
40. Mauer SM, Steffes M, Ellis E, et al: Structural-functional relationships in diabetic nephropathy. J Clin Invest 74:1143-1155, 1984
41. Lane PH, Steffes MW, Fioretto P, et al: Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int 43:661-667, 1993
42. Ueno M, Kawashima S, Nishi S, et al: Tubulointerstitial lesions in noninsulin-dependent diabetes mellitus. Kidney Int 52:S-191-S-194, 1997 (suppl 63)
43. Dzau VJ: Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation I-4-I-13, 1988 (suppl 1)
44. Johnston CI, Fabris B, Jandeleit K: Intrarenal renin-angiotensin in renal physiology and pathophysiology. Kidney Int 44:S59-S63, 1993 (suppl 42)
45. Anderson S, Jung FF, Ingelfinger JR: Renin-angiotensin system in diabetic rats: Functional, immunohistochemical, and molecular biologic correlations. Am J Physiol 265:F477-F486, 1993
46. Jaffa AA, Chai KX, Chao J, et al: Effects of diabetes and insulin on kallikrein and renin genes in the kidney. Kidney Int 41:789-795, 1992
47. Everett AD, Scott J, Wilfomg N, et al: Renin and angiotensinogen expression during evolution of diabetes. Hypertension 19:70-78, 1992
48. Gambaro G, Morbiato F, Cicerello E, et al: Captopril in the treatment of hypertension in type I and type II diabetic patients. J Hypertens 3:153-154, 1985 (suppl 2)
49. Baba T, Murabayashi S, Takabe K: Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type II (non-insulin-dependent) diabetic patients with microalbuminuria: A randomized controlled trial. Diabetologia 32:40-44, 1989
50. Bjork S, Nyberg G, Mulec H, et al: Benefical effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 293:471-474, 1986
51. Lewis EJ, Hunsicker LG, Bain RP, et al: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
52. Mulec H, Johnsen SA, Bjork S: Long-term enalapril treatment in diabetic nephropathy. Kidney Int 45:S141-S144, 1994 (suppl 45)
53. Mathiesen ER, Hommel E, Giese J, et al: Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. Br Med J 303:81-87, 1991
54. Ravid M, Savin H, Jutrin I, et al: Long-term-stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577-581, 1993
55. Kasiske BL, Kalil RSN, Ma JZ, et al: Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 118:129-139, 1993
56. Cooper ME, Allen TJ, O'Brien RC, et al: Nephropathy in a model combining genetic hypertension with diabetes: Enalapril vs hydralzine and metoprolol therapy. Diabetes 39:1575-1579, 1990
57. Sassy-Prigent C, Heudes D, Jouquey S, et al: Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats. Lab Invest 73:64-71, 1995
58. Anderson S, Rennke HG, Garcia DL, et al: Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 365:26-536, 1989
59. Velasquez MT, Striffler JS, Abraham AA, et al: Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat. Hypertension 30:1232-1237, 1997
60. Zatz R, Dunn BR, Meyer TW, et al: Prevention of diabetic glomerulopathy by pharmacologic amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
61. Wolf G, Ziyadeh FN: The role of angiotensin II in diabetic nephropathy: Emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 29:153-163, 1997
62. Wolf G, Haberstroh U, Neilson EG: Angiotensin II stimulates proliferation and collagen type I biosynthesis in cultured murine mesangial cells. Am J Pathol 140:95-107, 1992
63. Kagami S, Border WA, Miller DE, et al: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93:232-237, 1996
64. Egido J: Vasoactive hormones and renal sclerosis. Kidney Int 49:578-597, 1997